Athira Pharma Inc (NQ: ATHA )
2.370 +0.110 (+4.87%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
All News about Athira Pharma Inc
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023
Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system
Athira Outlines Possible Comeback For Alzheimer's Candidate
September 06, 2022
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Exposures Intellectual Property Legal Regulatory
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023
US stocks recorded losses for 2022. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's...
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
December 21, 2022
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models
The Dow Jones closed lower by nearly 350 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
December 01, 2022
Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
November 28, 2022
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 21, 2022
Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying
November 18, 2022
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Athira Pharma to Present at Stifel 2022 Healthcare Conference
November 09, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
November 07, 2022
Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following